The impact of LDV/SOF treatment on the work productivity of patients with chronic hepatitis C in Germany

Background: Chronic hepatitis C (CHC) is associated with increased presenteeism and absenteeism rates of patients. This creates a large economic burden for both employers and society. Ledipasvir/Sofosbuvir (LDV/SOF) is indicated for the treatment of CHC providing high efficacy, excellent tolerability and substantial quality of life improvement in clinical trials. An economic model was developed to assess the impact of LDV/SOF treatment vs. no treatment on work productivity for German CHC genotype 1 (GT1) patients. Methods: This cost-analysis model incorporates epidemiologic and economic data to estimate CHC GT1…